<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: Among B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (FL) more frequently show acquired, potential N-glycosylation sites (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>) within <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific immunoglobulin </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to extend this observation and to evaluate the pattern of presentation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> within five different forms of B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: We sequenced the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific immunoglobulin heavy chain variable region fragment, including complementarity-determining regions 2 and 3, of forty-seven consecutive patients with a B-cell <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> enrolled in idiotype vaccine clinical trials </plain></SENT>
<SENT sid="3" pm="."><plain>This sequencing approach is known to allow the identification of most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We then statistically analyzed differences in presentation pattern, in terms of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> histology, immunoglobulin isotype, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> location and amino acid composition </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> twenty-four FL cases presented with at least one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e>, whereas the vast majority of four B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types other than FL did not </plain></SENT>
<SENT sid="6" pm="."><plain>The non- FL group of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> included four cases of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, six of diffuse large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, seven mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and six small lymphocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Most IgM-bearing follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases featured their <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> within complementarity-determining region 2, as opposed to those bearing an IgG, which mostly displayed the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> within complementarity-determining region 3 </plain></SENT>
<SENT sid="8" pm="."><plain>The vast majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> located within either complementarity-determining region ended with a <z:chebi fb="0" ids="32848">serine residue</z:chebi>, whereas those located within framework regions mostly featured threonine as the last amino acid residue </plain></SENT>
<SENT sid="9" pm="."><plain>INTERPRETATION AND CONCLUSIONS: In our series, <z:hpo ids='HP_0000001'>all</z:hpo> cases of FL had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGS</z:e> within their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific immunoglobulin heavy chain variable regions </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, most B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> other than FL did not </plain></SENT>
<SENT sid="11" pm="."><plain>Further studies are warranted in order to establish the possible meaning of these findings in terms of disease pathogenesis, their diagnostic value in doubtful cases and their potential implications for immunotherapy </plain></SENT>
</text></document>